Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | HRH2 | P25021 | 1/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15809950 | 1.00 | KMT2A (0.62) | KMT2AHRH2HRH1CYP3A4CYP2D6 | |
| SCHEMBL15810046 | 0.95 | HRH2 (0.58) | KMT2AHRH2HRH1CYP3A4CYP2D6 | |
| SCHEMBL15810045 | 0.95 | HRH2 (0.58) | KMT2AHRH2HRH1CYP3A4CYP2D6 | |
| SCHEMBL5064576 | 0.95 | HRH2 (0.58) | KMT2AHRH2HRH1CYP3A4CYP2D6 | |
| SCHEMBL15809917 | 0.92 | HRH2 (0.55) | KMT2AHRH2HRH1CYP3A4CYP2D6 | |
| SCHEMBL15809918 | 0.92 | HRH2 (0.55) | KMT2AHRH2HRH1CYP3A4CYP2D6 | |
| SCHEMBL15810040 | 0.91 | P2RX7 (0.60) | KMT2AHRH2HRH1CYP3A4CYP2D6 | |
| SCHEMBL15810038 | 0.91 | P2RX7 (0.60) | KMT2AHRH2HRH1CYP3A4CYP2D6 | |
| SCHEMBL13291363 | 0.89 | KMT2A (0.64) | KMT2AHRH2HRH1CYP3A4MAPK1 | |
| SCHEMBL27340724 | 0.89 | KMT2A (0.64) | KMT2AHRH2HRH1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521715-B1 | PIPERAZINES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-25 | — | — | EP | disclosed |
| EP-1940814-B1 | PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-1940814-B1 | PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-8067419-B2 | N-[(S)-1-benzyl-2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-N-(4-pentyl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide, for example; antiprotozoa agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-29 | — | — | US | disclosed |
| US-8067419-B2 | N-[(S)-1-benzyl-2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-N-(4-pentyl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide, for example; antiprotozoa agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-29 | — | — | US | disclosed |
| US-8067419-B2 | N-[(S)-1-benzyl-2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-N-(4-pentyl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide, for example; antiprotozoa agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-29 | — | — | US | disclosed |
| US-20080234272-A1 | Novel Piperazines as Antimalarial Agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20080234272-A1 | Novel Piperazines as Antimalarial Agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20080234272-A1 | Novel Piperazines as Antimalarial Agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234272-A1 | Novel Piperazines as Antimalarial Agents | ITPA, PAK5, THPO | KMT2A 1152/4885HRH2 585/4885HRH1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.